News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Sales reflect continued strong growth in oncology and vaccines
International Business is expected to register double-digit growth in constant currency terms
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Subscribe To Our Newsletter & Stay Updated
